WAVE LIFE SCIENCES PTE. LTD. INVESTORS’ RIGHTS AGREEMENTRights Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 14th day of August, 2015, by and among Wave Life Sciences Pte. Ltd., a company incorporated in Singapore (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Commercial Lease AgreementCommercial Lease Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations • Massachusetts
This Commercial Lease Agreement (“Lease”) is made and effective January 1, 2010, by and between SNBL USA, Ltd. A Washington Corporation having a notice address of 6605 Merrill Creek Parkway, Everett, WA 98203 (“Landlord”) and Ontorii, Inc. a Delaware corporation having a notice address of 419 Western Ave. Boston MA 02135 (“Tenant”).
Amendment 1 to the Commercial Lease AgreementCommercial Lease Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations
This Amendment 1 to the Commercial Lease Agreement (“Lease”) is made and effective July 1, 2011, by and between SNBL USA, Ltd. a Washington Corporation having a notice address of 6605 Merrill Creek Parkway, Everett, WA 98203 (“Landlord”) and Ontorii, Inc., a Delaware corporation having a notice address of 419 Western Ave. Boston MA 02135 (“Tenant”).
MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations • Pennsylvania
THIS MASTER SPONSORED RESEARCH AGREEMENT (“Master Agreement”) is made and effective as of April 1, 2015 (the “Effective Date”), by and between WaVe Life Sciences PTE, Ltd with an office at 419 Western Avenue, Boston, Massachusetts, 02135 (“WaVe”), and The Children’s Hospital of Philadelphia, a Pennsylvania non-profit corporation with an office at 34th Street and Civic Center, Philadelphia, Pennsylvania 19104 (together with its affiliates “CHOP”). WaVe and CHOP are each hereafter referred to individually as a “Party” and together as the “Parties.”
CONFIDENTIAL CO-EXCLUSIVE LICENSE AGREEMENT between Max-Planck-Innovation GmbH a German corporation having a principal place of business at Amalienstr. 33, 80799 Muenchen, Germany - hereinafter “MI” - and Wave Life Sciences PTE, Ltd. a Singapore...License Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations
The Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (hereinafter “MPG”) is a German non-profit scientific research organisation. At the Max-Planck-Institute for Biophysical Chemistry in Goettingen (“MPI-BC”), a research institute of MPG, Dr. Thomas Tuschl and other scientists of MPI-BC have discovered the sequence and structural features of single-stranded RNA molecules required to mediate target-specific nucleic acid modifications by RNA interference ([***]). The aforementioned invention was funded by the German government. MPG has filed certain Patent Rights (as later defined herein) relating thereto.
